Back

Connect Biopharma shares plunge 32.46% after asthma trial misses primary endpoint

Verifying
  • Connect Biopharma released topline results from its global Phase 2 asthma trial.
  • Rademikibart cut treatment failures approximately 66% over 28 days versus placebo.
  • Connect Biopharma expects COPD trial data later this month and plans FDA discussions.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.